Anakinra Injection 100 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection(SQ)

Available Strengths: 100 mg/mL

Reference Brands: Kinerso, Kineret(US)

Category: Immune Disorder

Anakinra prefilled pens deliver IL-1 receptor antagonism, blocking IL-1 activity involved in inflammation. It effectively reduces symptoms of rheumatoid arthritis, Still’s disease, and other autoinflammatory conditions. Benefits include targeted therapy, ease of administration, consistent dosing, rapid symptom relief, and improved patient adherence, supporting better disease management.

Product Description: Anakinra prefilled pens, marketed as Kineret, are approved in both the US by the FDA and in the EU via EMA for rheumatoid arthritis, Still's disease, and autoinflammatory conditions. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety, manufacturing quality, and pharmacovigilance data. In the US, the FDA reviews detailed clinical trial and manufacturing information, while the EMA ensures compliance with regional standards. For guidance on dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Ensuring compliance is essential for timely approval, supporting safe and effective treatment options for autoimmune and autoinflammatory diseases worldwide.